JP2022500390A - キナーゼ阻害剤としてのアルキニルニコチンアミド化合物 - Google Patents
キナーゼ阻害剤としてのアルキニルニコチンアミド化合物 Download PDFInfo
- Publication number
- JP2022500390A JP2022500390A JP2021513385A JP2021513385A JP2022500390A JP 2022500390 A JP2022500390 A JP 2022500390A JP 2021513385 A JP2021513385 A JP 2021513385A JP 2021513385 A JP2021513385 A JP 2021513385A JP 2022500390 A JP2022500390 A JP 2022500390A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- following formula
- compound according
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 264
- 229940043355 kinase inhibitor Drugs 0.000 title abstract description 7
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 73
- 201000010099 disease Diseases 0.000 claims abstract description 43
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 20
- 201000011510 cancer Diseases 0.000 claims abstract description 15
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims abstract description 13
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims abstract description 4
- -1 Brk Proteins 0.000 claims description 70
- 239000000203 mixture Substances 0.000 claims description 35
- 208000035475 disorder Diseases 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 239000002775 capsule Substances 0.000 claims description 13
- 230000001225 therapeutic effect Effects 0.000 claims description 13
- 102000001253 Protein Kinase Human genes 0.000 claims description 12
- 108060006633 protein kinase Proteins 0.000 claims description 12
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 11
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims description 11
- 230000003287 optical effect Effects 0.000 claims description 10
- 150000001204 N-oxides Chemical class 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 9
- 239000012453 solvate Substances 0.000 claims description 8
- 102100026299 MAP kinase-interacting serine/threonine-protein kinase 1 Human genes 0.000 claims description 7
- 101710139011 MAP kinase-interacting serine/threonine-protein kinase 1 Proteins 0.000 claims description 7
- 235000015872 dietary supplement Nutrition 0.000 claims description 7
- 101001046427 Homo sapiens cGMP-dependent protein kinase 2 Proteins 0.000 claims description 6
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 claims description 6
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims description 6
- 102100022421 cGMP-dependent protein kinase 2 Human genes 0.000 claims description 6
- 230000003111 delayed effect Effects 0.000 claims description 6
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 5
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 5
- 108060006678 I-kappa-B kinase Proteins 0.000 claims description 5
- 102000001284 I-kappa-B kinase Human genes 0.000 claims description 5
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 5
- 101000983111 Homo sapiens Serine/threonine-protein kinase PAK 6 Proteins 0.000 claims description 4
- 102100033610 MAP kinase-interacting serine/threonine-protein kinase 2 Human genes 0.000 claims description 4
- 101710138999 MAP kinase-interacting serine/threonine-protein kinase 2 Proteins 0.000 claims description 4
- 102100026840 Serine/threonine-protein kinase PAK 6 Human genes 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 238000013270 controlled release Methods 0.000 claims description 4
- NZUUXQSBKZPFKK-UHFFFAOYSA-N 4-piperazin-1-ylmorpholine Chemical compound C1CNCCN1N1CCOCC1 NZUUXQSBKZPFKK-UHFFFAOYSA-N 0.000 claims description 3
- 102100033145 Cyclin-dependent kinase 19 Human genes 0.000 claims description 3
- 101000944345 Homo sapiens Cyclin-dependent kinase 19 Proteins 0.000 claims description 3
- 101001055092 Homo sapiens Mitogen-activated protein kinase kinase kinase 7 Proteins 0.000 claims description 3
- 101001055091 Homo sapiens Mitogen-activated protein kinase kinase kinase 8 Proteins 0.000 claims description 3
- 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 claims description 3
- 102100026907 Mitogen-activated protein kinase kinase kinase 8 Human genes 0.000 claims description 3
- 102100029680 Serine/threonine-protein kinase Kist Human genes 0.000 claims description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 239000005441 aurora Substances 0.000 claims description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims description 3
- 230000007246 mechanism Effects 0.000 claims description 3
- 101710082567 3-methylorcinaldehyde synthase Proteins 0.000 claims description 2
- 102100021546 60S ribosomal protein L10 Human genes 0.000 claims description 2
- 102100036409 Activated CDC42 kinase 1 Human genes 0.000 claims description 2
- 102100032306 Aurora kinase B Human genes 0.000 claims description 2
- 102100035080 BDNF/NT-3 growth factors receptor Human genes 0.000 claims description 2
- 102100027052 Bone morphogenetic protein receptor type-1B Human genes 0.000 claims description 2
- 101150047910 CSNK1D gene Proteins 0.000 claims description 2
- 102000004657 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Human genes 0.000 claims description 2
- 108010003721 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Proteins 0.000 claims description 2
- 102100034357 Casein kinase I isoform alpha Human genes 0.000 claims description 2
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 claims description 2
- 108010002947 Connectin Proteins 0.000 claims description 2
- 102000004726 Connectin Human genes 0.000 claims description 2
- 101150069913 Csk gene Proteins 0.000 claims description 2
- 108010093541 Cyclic GMP-Dependent Protein Kinase Type II Proteins 0.000 claims description 2
- 102000001379 Cyclic GMP-Dependent Protein Kinase Type II Human genes 0.000 claims description 2
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 claims description 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims description 2
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 claims description 2
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims description 2
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 claims description 2
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 claims description 2
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 claims description 2
- 102100034741 Cyclin-dependent kinase 20 Human genes 0.000 claims description 2
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 claims description 2
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 claims description 2
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 claims description 2
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 claims description 2
- 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 claims description 2
- 102100027907 Cytoplasmic tyrosine-protein kinase BMX Human genes 0.000 claims description 2
- 101100481404 Danio rerio tie1 gene Proteins 0.000 claims description 2
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims description 2
- 101100314281 Danio rerio trappc11 gene Proteins 0.000 claims description 2
- 101000737786 Daucus carota Calcium-dependent protein kinase Proteins 0.000 claims description 2
- 101001044938 Dictyostelium discoideum Diacylglycerol kinase A Proteins 0.000 claims description 2
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 claims description 2
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 claims description 2
- 102100040862 Dual specificity protein kinase CLK1 Human genes 0.000 claims description 2
- 102100036492 Dual specificity testis-specific protein kinase 1 Human genes 0.000 claims description 2
- 102100036498 Dual specificity testis-specific protein kinase 2 Human genes 0.000 claims description 2
- 102100028554 Dual specificity tyrosine-phosphorylation-regulated kinase 1A Human genes 0.000 claims description 2
- 102100033363 Dual specificity tyrosine-phosphorylation-regulated kinase 1B Human genes 0.000 claims description 2
- 102100023115 Dual specificity tyrosine-phosphorylation-regulated kinase 2 Human genes 0.000 claims description 2
- 108010055196 EphA2 Receptor Proteins 0.000 claims description 2
- 108010055191 EphA3 Receptor Proteins 0.000 claims description 2
- 108010055179 EphA4 Receptor Proteins 0.000 claims description 2
- 108010055155 EphA8 Receptor Proteins 0.000 claims description 2
- 108010055334 EphB2 Receptor Proteins 0.000 claims description 2
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims description 2
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 claims description 2
- 102100021616 Ephrin type-A receptor 4 Human genes 0.000 claims description 2
- 102100021601 Ephrin type-A receptor 8 Human genes 0.000 claims description 2
- 102100030779 Ephrin type-B receptor 1 Human genes 0.000 claims description 2
- 102100031968 Ephrin type-B receptor 2 Human genes 0.000 claims description 2
- 102100031982 Ephrin type-B receptor 3 Human genes 0.000 claims description 2
- 101100480905 Escherichia phage P1 tec gene Proteins 0.000 claims description 2
- 101150036586 FES gene Proteins 0.000 claims description 2
- 101150040897 Fgr gene Proteins 0.000 claims description 2
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims description 2
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims description 2
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims description 2
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims description 2
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 claims description 2
- 101000737787 Glycine max Calcium-dependent protein kinase SK5 Proteins 0.000 claims description 2
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 claims description 2
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 claims description 2
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 claims description 2
- 101001108634 Homo sapiens 60S ribosomal protein L10 Proteins 0.000 claims description 2
- 101001117935 Homo sapiens 60S ribosomal protein L15 Proteins 0.000 claims description 2
- 101000928956 Homo sapiens Activated CDC42 kinase 1 Proteins 0.000 claims description 2
- 101000798306 Homo sapiens Aurora kinase B Proteins 0.000 claims description 2
- 101000596896 Homo sapiens BDNF/NT-3 growth factors receptor Proteins 0.000 claims description 2
- 101000984546 Homo sapiens Bone morphogenetic protein receptor type-1B Proteins 0.000 claims description 2
- 101000994700 Homo sapiens Casein kinase I isoform alpha Proteins 0.000 claims description 2
- 101000945708 Homo sapiens Cyclin-dependent kinase 20 Proteins 0.000 claims description 2
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 claims description 2
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 claims description 2
- 101000935548 Homo sapiens Cytoplasmic tyrosine-protein kinase BMX Proteins 0.000 claims description 2
- 101000749294 Homo sapiens Dual specificity protein kinase CLK1 Proteins 0.000 claims description 2
- 101000714159 Homo sapiens Dual specificity testis-specific protein kinase 1 Proteins 0.000 claims description 2
- 101000714156 Homo sapiens Dual specificity testis-specific protein kinase 2 Proteins 0.000 claims description 2
- 101000838016 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1A Proteins 0.000 claims description 2
- 101000926738 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1B Proteins 0.000 claims description 2
- 101001049990 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 2 Proteins 0.000 claims description 2
- 101000967216 Homo sapiens Eosinophil cationic protein Proteins 0.000 claims description 2
- 101001064150 Homo sapiens Ephrin type-B receptor 1 Proteins 0.000 claims description 2
- 101001064458 Homo sapiens Ephrin type-B receptor 3 Proteins 0.000 claims description 2
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 claims description 2
- 101001066435 Homo sapiens Hepatocyte growth factor-like protein Proteins 0.000 claims description 2
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 claims description 2
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims description 2
- 101000926535 Homo sapiens Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 claims description 2
- 101000852483 Homo sapiens Interleukin-1 receptor-associated kinase 1 Proteins 0.000 claims description 2
- 101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 claims description 2
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims description 2
- 101001005602 Homo sapiens Mitogen-activated protein kinase kinase kinase 11 Proteins 0.000 claims description 2
- 101001005550 Homo sapiens Mitogen-activated protein kinase kinase kinase 14 Proteins 0.000 claims description 2
- 101001018196 Homo sapiens Mitogen-activated protein kinase kinase kinase 5 Proteins 0.000 claims description 2
- 101100243116 Homo sapiens PDK1 gene Proteins 0.000 claims description 2
- 101100463123 Homo sapiens PDK3 gene Proteins 0.000 claims description 2
- 101100463125 Homo sapiens PDK4 gene Proteins 0.000 claims description 2
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 claims description 2
- 101000595741 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Proteins 0.000 claims description 2
- 101000595746 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Proteins 0.000 claims description 2
- 101000595751 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Proteins 0.000 claims description 2
- 101000979748 Homo sapiens Protein NDRG1 Proteins 0.000 claims description 2
- 101001026864 Homo sapiens Protein kinase C gamma type Proteins 0.000 claims description 2
- 101000878540 Homo sapiens Protein-tyrosine kinase 2-beta Proteins 0.000 claims description 2
- 101000798015 Homo sapiens RAC-beta serine/threonine-protein kinase Proteins 0.000 claims description 2
- 101000712530 Homo sapiens RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 claims description 2
- 101000927796 Homo sapiens Rho guanine nucleotide exchange factor 7 Proteins 0.000 claims description 2
- 101000669917 Homo sapiens Rho-associated protein kinase 1 Proteins 0.000 claims description 2
- 101000669921 Homo sapiens Rho-associated protein kinase 2 Proteins 0.000 claims description 2
- 101001051714 Homo sapiens Ribosomal protein S6 kinase beta-2 Proteins 0.000 claims description 2
- 101000628647 Homo sapiens Serine/threonine-protein kinase 24 Proteins 0.000 claims description 2
- 101000701401 Homo sapiens Serine/threonine-protein kinase 38 Proteins 0.000 claims description 2
- 101000880431 Homo sapiens Serine/threonine-protein kinase 4 Proteins 0.000 claims description 2
- 101000695043 Homo sapiens Serine/threonine-protein kinase BRSK1 Proteins 0.000 claims description 2
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 claims description 2
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 claims description 2
- 101000913761 Homo sapiens Serine/threonine-protein kinase ICK Proteins 0.000 claims description 2
- 101000987310 Homo sapiens Serine/threonine-protein kinase PAK 2 Proteins 0.000 claims description 2
- 101000987315 Homo sapiens Serine/threonine-protein kinase PAK 3 Proteins 0.000 claims description 2
- 101000987295 Homo sapiens Serine/threonine-protein kinase PAK 5 Proteins 0.000 claims description 2
- 101000665442 Homo sapiens Serine/threonine-protein kinase TBK1 Proteins 0.000 claims description 2
- 101000649929 Homo sapiens Serine/threonine-protein kinase VRK1 Proteins 0.000 claims description 2
- 101000984551 Homo sapiens Tyrosine-protein kinase Blk Proteins 0.000 claims description 2
- 101001009087 Homo sapiens Tyrosine-protein kinase HCK Proteins 0.000 claims description 2
- 101001050476 Homo sapiens Tyrosine-protein kinase ITK/TSK Proteins 0.000 claims description 2
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 claims description 2
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims description 2
- 101000739853 Homo sapiens [3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] kinase, mitochondrial Proteins 0.000 claims description 2
- 101001117143 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial Proteins 0.000 claims description 2
- 101001046426 Homo sapiens cGMP-dependent protein kinase 1 Proteins 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 101150026109 INSR gene Proteins 0.000 claims description 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims description 2
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 claims description 2
- 102100036342 Interleukin-1 receptor-associated kinase 1 Human genes 0.000 claims description 2
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 108010075654 MAP Kinase Kinase Kinase 1 Proteins 0.000 claims description 2
- 102100034069 MAP kinase-activated protein kinase 2 Human genes 0.000 claims description 2
- 108010041955 MAP-kinase-activated kinase 2 Proteins 0.000 claims description 2
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims description 2
- 102100033115 Mitogen-activated protein kinase kinase kinase 1 Human genes 0.000 claims description 2
- 102100025207 Mitogen-activated protein kinase kinase kinase 11 Human genes 0.000 claims description 2
- 102100025211 Mitogen-activated protein kinase kinase kinase 14 Human genes 0.000 claims description 2
- 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 claims description 2
- 101710132461 Molybdenum cofactor sulfurase Proteins 0.000 claims description 2
- 101100262697 Mus musculus Axl gene Proteins 0.000 claims description 2
- 101100405128 Mus musculus Nr4a3 gene Proteins 0.000 claims description 2
- 101100480907 Mus musculus Tec gene Proteins 0.000 claims description 2
- 101100481410 Mus musculus Tek gene Proteins 0.000 claims description 2
- 101100481406 Mus musculus Tie1 gene Proteins 0.000 claims description 2
- 102100037837 Nucleoporin Nup37 Human genes 0.000 claims description 2
- 101100381429 Oryza sativa subsp. japonica BADH2 gene Proteins 0.000 claims description 2
- 101700056750 PAK1 Proteins 0.000 claims description 2
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 claims description 2
- 102100036061 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Human genes 0.000 claims description 2
- 102100036056 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Human genes 0.000 claims description 2
- 102100036052 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Human genes 0.000 claims description 2
- 101800000618 Protein kinase C delta type catalytic subunit Proteins 0.000 claims description 2
- 102100037314 Protein kinase C gamma type Human genes 0.000 claims description 2
- 102100021004 Protein sidekick-1 Human genes 0.000 claims description 2
- 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 claims description 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims description 2
- 102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 claims description 2
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 claims description 2
- 101150077555 Ret gene Proteins 0.000 claims description 2
- 102100039313 Rho-associated protein kinase 1 Human genes 0.000 claims description 2
- 102100039314 Rho-associated protein kinase 2 Human genes 0.000 claims description 2
- 101710119197 Ribosomal protein S6 kinase alpha-1 Proteins 0.000 claims description 2
- 102100033536 Ribosomal protein S6 kinase alpha-1 Human genes 0.000 claims description 2
- 101710119185 Ribosomal protein S6 kinase alpha-2 Proteins 0.000 claims description 2
- 102100033534 Ribosomal protein S6 kinase alpha-2 Human genes 0.000 claims description 2
- 101710119204 Ribosomal protein S6 kinase alpha-3 Proteins 0.000 claims description 2
- 102100033643 Ribosomal protein S6 kinase alpha-3 Human genes 0.000 claims description 2
- 102100024917 Ribosomal protein S6 kinase beta-2 Human genes 0.000 claims description 2
- 101001117144 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) [Pyruvate dehydrogenase (acetyl-transferring)] kinase 1, mitochondrial Proteins 0.000 claims description 2
- 101000734335 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) [Pyruvate dehydrogenase (acetyl-transferring)] kinase 2, mitochondrial Proteins 0.000 claims description 2
- 102100026764 Serine/threonine-protein kinase 24 Human genes 0.000 claims description 2
- 102100030514 Serine/threonine-protein kinase 38 Human genes 0.000 claims description 2
- 102100037629 Serine/threonine-protein kinase 4 Human genes 0.000 claims description 2
- 102100028623 Serine/threonine-protein kinase BRSK1 Human genes 0.000 claims description 2
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 claims description 2
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 claims description 2
- 102100026621 Serine/threonine-protein kinase ICK Human genes 0.000 claims description 2
- 101710106482 Serine/threonine-protein kinase Kist Proteins 0.000 claims description 2
- 102100027939 Serine/threonine-protein kinase PAK 2 Human genes 0.000 claims description 2
- 102100027911 Serine/threonine-protein kinase PAK 3 Human genes 0.000 claims description 2
- 102100038192 Serine/threonine-protein kinase TBK1 Human genes 0.000 claims description 2
- 102100028235 Serine/threonine-protein kinase VRK1 Human genes 0.000 claims description 2
- 101150110875 Syk gene Proteins 0.000 claims description 2
- 102100030168 Testis-specific serine/threonine-protein kinase 3 Human genes 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 102100027053 Tyrosine-protein kinase Blk Human genes 0.000 claims description 2
- 102100027389 Tyrosine-protein kinase HCK Human genes 0.000 claims description 2
- 102100023345 Tyrosine-protein kinase ITK/TSK Human genes 0.000 claims description 2
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 claims description 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims description 2
- 101150060655 WNK1 gene Proteins 0.000 claims description 2
- 101150040313 Wee1 gene Proteins 0.000 claims description 2
- 101001001642 Xenopus laevis Serine/threonine-protein kinase pim-3 Proteins 0.000 claims description 2
- 102100037607 [3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] kinase, mitochondrial Human genes 0.000 claims description 2
- 102100024148 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Human genes 0.000 claims description 2
- 102100024150 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial Human genes 0.000 claims description 2
- 102100034824 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial Human genes 0.000 claims description 2
- 102100034825 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial Human genes 0.000 claims description 2
- 102100022422 cGMP-dependent protein kinase 1 Human genes 0.000 claims description 2
- 108010049611 glycogen synthase kinase 3 alpha Proteins 0.000 claims description 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000030151 polycystic kidney disease 3 with or without polycystic liver disease Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 108010090229 tropomyosin kinase Proteins 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000010837 Diabetic eye disease Diseases 0.000 claims 1
- 102100023275 Dual specificity mitogen-activated protein kinase kinase 3 Human genes 0.000 claims 1
- 102100023274 Dual specificity mitogen-activated protein kinase kinase 4 Human genes 0.000 claims 1
- 102100023401 Dual specificity mitogen-activated protein kinase kinase 6 Human genes 0.000 claims 1
- 102100023332 Dual specificity mitogen-activated protein kinase kinase 7 Human genes 0.000 claims 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims 1
- 101100306202 Escherichia coli (strain K12) rpoB gene Proteins 0.000 claims 1
- 101001115394 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 3 Proteins 0.000 claims 1
- 101001115395 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 4 Proteins 0.000 claims 1
- 101000624426 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 6 Proteins 0.000 claims 1
- 101000624594 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 7 Proteins 0.000 claims 1
- 101001002695 Homo sapiens Integrin-linked protein kinase Proteins 0.000 claims 1
- 101001137642 Homo sapiens Kinase suppressor of Ras 1 Proteins 0.000 claims 1
- 101001042360 Homo sapiens LIM domain kinase 2 Proteins 0.000 claims 1
- 101001052490 Homo sapiens Mitogen-activated protein kinase 3 Proteins 0.000 claims 1
- 101001052477 Homo sapiens Mitogen-activated protein kinase 4 Proteins 0.000 claims 1
- 101000950710 Homo sapiens Mitogen-activated protein kinase 6 Proteins 0.000 claims 1
- 101000950687 Homo sapiens Mitogen-activated protein kinase 7 Proteins 0.000 claims 1
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 claims 1
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 claims 1
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 claims 1
- 101001051767 Homo sapiens Protein kinase C beta type Proteins 0.000 claims 1
- 101000885321 Homo sapiens Serine/threonine-protein kinase DCLK1 Proteins 0.000 claims 1
- 101000588540 Homo sapiens Serine/threonine-protein kinase Nek6 Proteins 0.000 claims 1
- 101000588553 Homo sapiens Serine/threonine-protein kinase Nek9 Proteins 0.000 claims 1
- 101000577652 Homo sapiens Serine/threonine-protein kinase PRP4 homolog Proteins 0.000 claims 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 claims 1
- 101000606067 Homo sapiens Tyrosine-protein kinase TXK Proteins 0.000 claims 1
- 101000577737 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp4 Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 102100021001 Kinase suppressor of Ras 1 Human genes 0.000 claims 1
- 102100021756 LIM domain kinase 2 Human genes 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 101150058160 Lyn gene Proteins 0.000 claims 1
- 108010068342 MAP Kinase Kinase 1 Proteins 0.000 claims 1
- 108010068353 MAP Kinase Kinase 2 Proteins 0.000 claims 1
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 claims 1
- 102100024189 Mitogen-activated protein kinase 4 Human genes 0.000 claims 1
- 102100037801 Mitogen-activated protein kinase 6 Human genes 0.000 claims 1
- 102100037805 Mitogen-activated protein kinase 7 Human genes 0.000 claims 1
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 claims 1
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 claims 1
- 102100027983 Molybdenum cofactor sulfurase Human genes 0.000 claims 1
- 101100306001 Mus musculus Mst1r gene Proteins 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102100024923 Protein kinase C beta type Human genes 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 102100039758 Serine/threonine-protein kinase DCLK1 Human genes 0.000 claims 1
- 102100031401 Serine/threonine-protein kinase Nek6 Human genes 0.000 claims 1
- 102100031398 Serine/threonine-protein kinase Nek9 Human genes 0.000 claims 1
- 102100027910 Serine/threonine-protein kinase PAK 1 Human genes 0.000 claims 1
- 102100028868 Serine/threonine-protein kinase PRP4 homolog Human genes 0.000 claims 1
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 claims 1
- 101710181599 Serine/threonine-protein kinase STK11 Proteins 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 230000000938 luteal effect Effects 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- JTSLALYXYSRPGW-UHFFFAOYSA-N n-[5-(4-cyanophenyl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC(C1=C2)=CNC1=NC=C2C1=CC=C(C#N)C=C1 JTSLALYXYSRPGW-UHFFFAOYSA-N 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 239000002137 L01XE24 - Ponatinib Substances 0.000 description 47
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 description 47
- 229960001131 ponatinib Drugs 0.000 description 47
- 239000003814 drug Substances 0.000 description 46
- 229940079593 drug Drugs 0.000 description 43
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 30
- 239000000243 solution Substances 0.000 description 23
- 239000003826 tablet Substances 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 21
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 21
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 20
- 108091000080 Phosphotransferase Proteins 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 102000020233 phosphotransferase Human genes 0.000 description 20
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 20
- 239000000126 substance Substances 0.000 description 16
- 238000011282 treatment Methods 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 14
- 150000001345 alkine derivatives Chemical class 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical group NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 11
- 239000007789 gas Substances 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 11
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 description 10
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 description 10
- 229910052786 argon Inorganic materials 0.000 description 10
- 239000012267 brine Substances 0.000 description 10
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical group NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 8
- 0 CN1C(*)(*)C(*)(*)N(Cc(cc2)c(C(F)(F)F)cc2NC(c2cc(C#Cc3cnc4[n]3cccc4)cnc2)=O)C(*)(*)C1(*)* Chemical compound CN1C(*)(*)C(*)(*)N(Cc(cc2)c(C(F)(F)F)cc2NC(c2cc(C#Cc3cnc4[n]3cccc4)cnc2)=O)C(*)(*)C1(*)* 0.000 description 8
- 102000001332 SRC Human genes 0.000 description 8
- 108060006706 SRC Proteins 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 239000003937 drug carrier Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 108091008794 FGF receptors Proteins 0.000 description 7
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 description 7
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 239000003446 ligand Substances 0.000 description 6
- 238000013268 sustained release Methods 0.000 description 6
- 239000012730 sustained-release form Substances 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 229940127557 pharmaceutical product Drugs 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 229940000425 combination drug Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 150000004668 long chain fatty acids Chemical class 0.000 description 4
- 229940126701 oral medication Drugs 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 3
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000007910 chewable tablet Substances 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 239000013066 combination product Substances 0.000 description 3
- 229940127555 combination product Drugs 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 150000005480 nicotinamides Chemical class 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 3
- 102200039431 rs121913488 Human genes 0.000 description 3
- 229960001153 serine Drugs 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- 229960002930 sirolimus Drugs 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- XXUNIGZDNWWYED-UHFFFAOYSA-N 2-methylbenzamide Chemical class CC1=CC=CC=C1C(N)=O XXUNIGZDNWWYED-UHFFFAOYSA-N 0.000 description 2
- 101001082110 Acanthamoeba polyphaga mimivirus Eukaryotic translation initiation factor 4E homolog Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 101001082109 Danio rerio Eukaryotic translation initiation factor 4E-1B Proteins 0.000 description 2
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 2
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000762967 Homo sapiens Lymphokine-activated killer T-cell-originated protein kinase Proteins 0.000 description 2
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 2
- 101000628949 Homo sapiens Mitogen-activated protein kinase 10 Proteins 0.000 description 2
- 101000628967 Homo sapiens Mitogen-activated protein kinase 11 Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 102100026753 Lymphokine-activated killer T-cell-originated protein kinase Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 229940124647 MEK inhibitor Drugs 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 2
- 102100026931 Mitogen-activated protein kinase 10 Human genes 0.000 description 2
- 102100026929 Mitogen-activated protein kinase 11 Human genes 0.000 description 2
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 description 2
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 description 2
- 102100031206 Serine/threonine-protein kinase N1 Human genes 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 201000009036 biliary tract cancer Diseases 0.000 description 2
- 208000020790 biliary tract neoplasm Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 229960002743 glutamine Drugs 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229940124303 multikinase inhibitor Drugs 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000473391 Archosargus rhomboidalis Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- JAVMJOXBLVUDEX-UHFFFAOYSA-N CN1CCN(Cc(cc2)c(C(F)(F)F)cc2NC(c2cc(C#Cc3cnc4[n]3cncc4)cnc2)=O)CC1 Chemical compound CN1CCN(Cc(cc2)c(C(F)(F)F)cc2NC(c2cc(C#Cc3cnc4[n]3cncc4)cnc2)=O)CC1 JAVMJOXBLVUDEX-UHFFFAOYSA-N 0.000 description 1
- 101100015811 Caenorhabditis elegans grk-2 gene Proteins 0.000 description 1
- OGJPTCOULZFTFA-UHFFFAOYSA-N Cc1cc2ncc(C#Cc3cncc(C(Nc4cc(C(F)(F)F)c(CN5CCN(C)CC5)cc4)=O)c3)[n]2cn1 Chemical compound Cc1cc2ncc(C#Cc3cncc(C(Nc4cc(C(F)(F)F)c(CN5CCN(C)CC5)cc4)=O)c3)[n]2cn1 OGJPTCOULZFTFA-UHFFFAOYSA-N 0.000 description 1
- IFYKNEXHEDPXKE-UHFFFAOYSA-N Cc1cnc[n]2c1ncc2C#Cc1cncc(C(Nc2cc(C(F)(F)F)c(CN3CCN(C)CC3)cc2)=O)c1 Chemical compound Cc1cnc[n]2c1ncc2C#Cc1cncc(C(Nc2cc(C(F)(F)F)c(CN3CCN(C)CC3)cc2)=O)c1 IFYKNEXHEDPXKE-UHFFFAOYSA-N 0.000 description 1
- DYQLWBOLIRWGHY-UHFFFAOYSA-N Cc1nccc2ncc(C#Cc3cncc(C(Nc4cc(C(F)(F)F)c(CN5CCN(C)CC5)cc4)=O)c3)[n]12 Chemical compound Cc1nccc2ncc(C#Cc3cncc(C(Nc4cc(C(F)(F)F)c(CN5CCN(C)CC5)cc4)=O)c3)[n]12 DYQLWBOLIRWGHY-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 102100033245 Cyclin-dependent kinase 16 Human genes 0.000 description 1
- 102100033144 Cyclin-dependent kinase 18 Human genes 0.000 description 1
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 102100038606 Death-associated protein kinase 3 Human genes 0.000 description 1
- UQBOJOOOTLPNST-UHFFFAOYSA-N Dehydroalanine Chemical compound NC(=C)C(O)=O UQBOJOOOTLPNST-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 229940099567 Dopamine D4 receptor agonist Drugs 0.000 description 1
- 102000003962 Dopamine D4 receptors Human genes 0.000 description 1
- 108090000357 Dopamine D4 receptors Proteins 0.000 description 1
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- 101710146529 Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 description 1
- 102100023114 Dual specificity tyrosine-phosphorylation-regulated kinase 3 Human genes 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229940124602 FDA-approved drug Drugs 0.000 description 1
- 101150093530 Fer gene Proteins 0.000 description 1
- 102100024802 Fibroblast growth factor 23 Human genes 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 101150023186 GRK1 gene Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101150017137 Haspin gene Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101000944357 Homo sapiens Cyclin-dependent kinase 16 Proteins 0.000 description 1
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 description 1
- 101000956149 Homo sapiens Death-associated protein kinase 3 Proteins 0.000 description 1
- 101001049991 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 3 Proteins 0.000 description 1
- 101001010783 Homo sapiens Endoribonuclease Proteins 0.000 description 1
- 101001051973 Homo sapiens Fibroblast growth factor 23 Proteins 0.000 description 1
- 101000878536 Homo sapiens Focal adhesion kinase 1 Proteins 0.000 description 1
- 101000628954 Homo sapiens Mitogen-activated protein kinase 12 Proteins 0.000 description 1
- 101001059991 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 1 Proteins 0.000 description 1
- 101001059990 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 2 Proteins 0.000 description 1
- 101001059984 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 4 Proteins 0.000 description 1
- 101001011663 Homo sapiens Mixed lineage kinase domain-like protein Proteins 0.000 description 1
- 101000613563 Homo sapiens PAS domain-containing serine/threonine-protein kinase Proteins 0.000 description 1
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 description 1
- 101001089266 Homo sapiens Receptor-interacting serine/threonine-protein kinase 3 Proteins 0.000 description 1
- 101001089248 Homo sapiens Receptor-interacting serine/threonine-protein kinase 4 Proteins 0.000 description 1
- 101000697608 Homo sapiens Serine/threonine-protein kinase 38-like Proteins 0.000 description 1
- 101001129076 Homo sapiens Serine/threonine-protein kinase N1 Proteins 0.000 description 1
- 101001123846 Homo sapiens Serine/threonine-protein kinase Nek1 Proteins 0.000 description 1
- 101000601441 Homo sapiens Serine/threonine-protein kinase Nek2 Proteins 0.000 description 1
- 101000770770 Homo sapiens Serine/threonine-protein kinase WNK1 Proteins 0.000 description 1
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical compound OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108020005198 Long Noncoding RNA Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 1
- 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102100026932 Mitogen-activated protein kinase 12 Human genes 0.000 description 1
- 102100028199 Mitogen-activated protein kinase kinase kinase kinase 1 Human genes 0.000 description 1
- 102100028192 Mitogen-activated protein kinase kinase kinase kinase 2 Human genes 0.000 description 1
- 102100028194 Mitogen-activated protein kinase kinase kinase kinase 4 Human genes 0.000 description 1
- 102100030177 Mixed lineage kinase domain-like protein Human genes 0.000 description 1
- 102100029166 NT-3 growth factor receptor Human genes 0.000 description 1
- 101150117329 NTRK3 gene Proteins 0.000 description 1
- 102100040902 PAS domain-containing serine/threonine-protein kinase Human genes 0.000 description 1
- 108010039798 PCTAIRE-3 protein kinase Proteins 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 206010073391 Platelet dysfunction Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102100040101 Proto-oncogene serine/threonine-protein kinase mos Human genes 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 108010079933 Receptor-Interacting Protein Serine-Threonine Kinase 2 Proteins 0.000 description 1
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 description 1
- 102100022502 Receptor-interacting serine/threonine-protein kinase 2 Human genes 0.000 description 1
- 102100033729 Receptor-interacting serine/threonine-protein kinase 3 Human genes 0.000 description 1
- 102100033734 Receptor-interacting serine/threonine-protein kinase 4 Human genes 0.000 description 1
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 description 1
- RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 1
- 102100027898 Serine/threonine-protein kinase 38-like Human genes 0.000 description 1
- 102100028751 Serine/threonine-protein kinase Nek1 Human genes 0.000 description 1
- 102100037703 Serine/threonine-protein kinase Nek2 Human genes 0.000 description 1
- 102100029064 Serine/threonine-protein kinase WNK1 Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100022356 Tyrosine-protein kinase Mer Human genes 0.000 description 1
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 108010018804 c-Mer Tyrosine Kinase Proteins 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000004706 cardiovascular dysfunction Effects 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003844 drug implant Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229950006304 gilteritinib Drugs 0.000 description 1
- GYQYAJJFPNQOOW-UHFFFAOYSA-N gilteritinib Chemical compound N1=C(NC2CCOCC2)C(CC)=NC(C(N)=O)=C1NC(C=C1OC)=CC=C1N(CC1)CCC1N1CCN(C)CC1 GYQYAJJFPNQOOW-UHFFFAOYSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 201000005991 hyperphosphatemia Diseases 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- OSILBMSORKFRTB-UHFFFAOYSA-N isoquinolin-1-amine Chemical class C1=CC=C2C(N)=NC=CC2=C1 OSILBMSORKFRTB-UHFFFAOYSA-N 0.000 description 1
- VYCKDIRCVDCQAE-UHFFFAOYSA-N isoquinolin-3-amine Chemical class C1=CC=C2C=NC(N)=CC2=C1 VYCKDIRCVDCQAE-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000008185 minitablet Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000003365 myofibril Anatomy 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011865 proteolysis targeting chimera technique Methods 0.000 description 1
- 229940124823 proteolysis targeting chimeric molecule Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000004892 pyridazines Chemical class 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229960002718 selenomethionine Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 108010026668 snake venom protein C activator Proteins 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007886 soft shell capsule Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
本出願は、2018年9月12日に出願された米国仮特許出願第62/730,046号明細書の優先権を主張する。この特許出願の全内容及び開示は、参照により本明細書に組み込まれる。
他に定義されない限り、本明細書で使用されるあらゆる技術用語及び科学用語は、特許請求された主題が属する分野の当業者によって一般に理解されるのと同じ意味を有する。本明細書中に用語の定義が複数ある場合は、この項の定義が優先される。本明細書で参照されるあらゆる特許、特許出願、刊行物、ならびに公開されたヌクレオチド及びアミノ酸配列(例えば、GenBank又は他のデータベースで利用可能な配列)は、参照により組み込まれる。URL又は他のそのような識別子もしくはアドレスを参照する場合、そのような識別子は変化し得、インターネット上の特定の情報は移り変わり得るが、インターネットを検索することによって同等の情報が見出され得ることが理解される。それらへの言及は、そのような情報の入手可能性と一般への普及とを証明している。
本発明は、様々な修正及び代替形態の影響を受けやすいが、その特定の実施形態は、例として図面に示され、以下に詳細に説明される。ただし、開示された特定の形態に本発明を限定することは意図されず、逆に、本発明は、本発明の趣旨及び範囲内にあるすべての修正、同等物及び代替物を網羅するものであることを理解されたい。
式中、Y==アミド;O−アルキル、例えば、OMe、OEt、OPr、OBu、OiPr、OCF2、OCF3;NH2、NH−アルキル、例えば、NHMe、NHEt;N−(アルキル)2又はN−(ヘテロアルキル)2、例えば、NMe2、モルホリノ、ピペラジン;CN、Cl、Br、iPr、Et、シクロプロピル、ブチル、CF3、CHF2、CH2−ピペラジン類似体、CH2−モルホリン類似体、CH2−ピペリジン類似体、CH2−ピロリジン類似体、CH2−アゼチジン類似体などであり、X1〜X7=CH、CY又はNである。この一般的な化合物は、以下、式(I)と呼ばれる。
例1
ポナチニブは、心血管関連キナーゼに対してHSN748よりも放縦である
ABL1及びFLT3は、それぞれCML及びAMLでは変異している。ポナチニブ及びHSN748は、ABL1、ABL1(T315I)及びFLT3−ITDに対して同様の活性を有する。興味深いことに、HSN748は、FLT3(D835Y)キナーゼに対してポナチニブよりも顕著に低いIC50を有する(ポナチニブの173nMに対して、HSN748の14nMというIC50を比較されたい。表2を参照)。臨床で使用されるほとんどのFLT3阻害剤は初期に効果を示すが、患者は数カ月以内にキナーゼ変異により再発し、治療効果が低下する20。D835変異は、TKIキザルチニブを使用した試験で観察された最も頻繁な変異の1つである21。したがって、薬剤耐性AML(キナーゼ変異による)では、HSN748はポナチニブよりも優れた治療選択肢となる可能性がある。
HSN748は、AML細胞株をポナチニブよりも強力に阻害する
本発明者らは、ポナチニブ及びHSN748による、FLT3、ABL1、RET及びFGFRによって引き起こされたがんの阻害の程度が、キナーゼ阻害の序列を反映していたかどうかの試験に進んだ。MV4−11(FLT3)、K562(ABL1)及びLC2/ad(RET)に対する両化合物による増殖阻害のIC50は類似していた。HSN748は、キザルチニブ耐性AML(MOLM14−D835Y細胞株)を阻害する点でポナチニブよりも優れていた(HSN748の0.69nM及びポナチニブの52.6nMというIC50を比較されたい)。ギルテリチニブ耐性AML細胞株であるMolm14(ITD、F691L)でも、HSN748はポナチニブよりも強力であった(IC50は、HSN748では0.18nM、ポナチニブでは6.8nM)。
Claims (39)
- 請求項1から29のいずれか一項に記載の化合物、又はその薬学的に許容される塩、N−オキシド、水和物、溶媒、互変異性体もしくは光学異性体、及び薬学的に許容される担体もしくは希釈剤を含む医薬組成物。
- それを必要とする対象のがんを改善する方法であって、請求項1から29のいずれか一項に記載の化合物、もしくはその薬学的に許容される塩、N−オキシド、水和物、溶媒和物、互変異性体もしくは光学異性体、又は請求項30に記載の医薬組成物の治療上有効量を対象に投与することを含む方法。
- がんが、急性骨髄性白血病、慢性骨髄性白血病、卵巣がん、子宮頸がん、膵臓がん、乳がん、脳がん、皮膚がん、肺がん、前立腺がん、リンパ腫、白血病、結腸がん、頭部がん、頸部がん、甲状腺がん、腎がん、肝がん及び胃がんからなる群から選択される、請求項31に記載の方法。
- それを必要とする対象におけるタンパク質キナーゼに関連する疾患又は障害を改善する方法であって、請求項1から29のいずれか一項に記載の化合物、もしくはその薬学的に許容される塩、N−オキシド、水和物、溶媒和物、互変異性体もしくは光学異性体、又は請求項29に記載の医薬組成物の治療上有効量を対象に投与することを含む方法。
- タンパク質キナーゼが、Abl、Abl2、AFK、ALK、AMPK_群、ATM、ATR、オーロラA、オーロラB、Axl、BCKDK、BLK、BMPR1B、BMX、Brk、BRSK1、BTK、CaM−KIα、CaM−KIIα、CaMKK_群、CaM−KIV、CaM−KKα、CaM−KKβ、CCDPK、CCRK、CDK1、CDK11、CDK2、CDK4、CDK5、CDK6、CDK7、CDK9、CDK_群、CDPK、Chak1、CHK1、CHK2、CK1α、CK1δ、CK1ε、CK1_群、CK2α、CK2_β、CK2_群、CLK1、CSF1R、Csk、DAPK1、DAPK2、DAPK3、DAPK_群、DCAMKL1、DMPK_群、DNA−PK、DYRK1A、DYRK1B、DYRK2、DYRK3、eEF2K、Eg3キナーゼ、EGFR、EIF2AK2、EphA2、EphA3、EphA4、EphA8、EphB1、EphB2、EphB3、EphB5、ErbB2、FAK、Fer、Fes、FGFR1、FGFR3、FGFR4、FGFR_群、Fgr、FLT1、FLT3、FLT4、Fyn、GRK−1、GRK−2、GRK−3、GRK−4、GRK−5、GRK−6、GRK_群、GSK−3α、GSK−3β、GSK−3_群、HCK、HIPK2、HIPK3、HRI、ICK、IGF1R、IKK−α、IKK−β、IKK−ε ILK、InsR、IPL1、IRAK1、IRAK4、ITK、JAK1、JAK2、JAK3、JAK_群、JNK_群、KDR、KIS、Kit、KSR1、Lck、LIMK1、LIMK2、LKB1、LOK、Lyn、MAP2K1、MAP2K2、MAP2K3、MAP2K4、MAP2K6、MAP2K7、MAPK2_群、MAP3K1、MAP3K11、MAP3K14、MAP3K5、MAP3K7、MAP3K8、MAPK3_群、MAP4K1、MAP4K2、MAP4K4、MAPK1、MAPK10、MAPK11、MAPK12、MAPK13、MAPK14、MAPK3、MAPK4、MAPK6、MAPK7、MAPK8、MAPK9、MAPK_群、MAPKAPK2、MARK_群、Mer、Met、MHCK、MLCK_群、Mnk1、Mnk2、MOS、MRCKa、MST1、MST3、mTOR、NDR1、NDR2、NEK1、NEK2、NEK6、NEK9、NEK_群、NLK、NuaK1、p37キナーゼ、p38_群、p70S6K、p70S6Kb、P70S6K_群、PAK1、PAK2、PAK3、PAK5、PAK6、PAK_群、PASK、P−CIP2、PCTAIRE1、PDGFRα、PDGFRβ、PDGFR_群、PDHK1、PDHK2、PDHK3、PDHK4、PDK−1、PDK−2、PDK_群、PHK_群、PIK3CA、PIK3CB、PIK3CD、PIK3CG、Pim−1、PKAα、Pka_群、PKBβ、PKB_群、PKCα、PKCβ、PKCδ、PKCε、PKCη、PKCγ、PKCι、PKCθ、PKCζ、PKC_群、PKD1、PKD2、PKD3、PKG1/cGK−I、PKG2/cGK−II、PKG2/cGK_群、PKN1、PLK1、PLK2、PLK3、PRP4、PYK2、RAF1、Ret、ROCK1、ROCK2、Ron、RPL10、RSK−1、RSK−2、RSK−3、RSK−5、SDK1、SGK_群、SIK、Sky、Src、Src_群、STLK3、Syk、TBK1、Tec、TESK1、TESK2、TGFbR1、TGFbR2、Tie1、Tie2、タイチンキナーゼ、TNK2、TRKA、TRKB、トロポミオシンキナーゼ、TSSK3、TXK、Tyk2、TYK2、VRK1、Wee1、Wnk1、WNK1、Yes又はZAP70である、請求項33に記載の方法。
- 疾患又は障害が、がん、糖尿病、マラリア、ウイルス感染症、心血管性及び高血圧、CNS及び神経変性、骨粗鬆症、肺線維症、網膜炎色素症(retinitis pigmentosis)、滲出型黄斑変性、デュシェンヌ型筋ジストロフィー、糖尿病性眼疾患、炎症及び自己免疫性、又はアレルギーである、請求項33に記載の方法。
- 装置と、装置に収容された組成物の少なくとも1つの投薬量とを備える治療送達器具であって、組成物が、治療上有効量の請求項1から29に記載の化合物もしくは化合物の組合せ、もしくはその薬学的に許容される塩、N−オキシド、水和物、溶媒和物、互変異性体もしくは光学異性体、又は請求項30に記載の医薬組成物である治療送達器具。
- カプセル、ポリピル、錠剤、経皮パッチ、栄養補助食品又はそれらの組合せからなる群から選択される送達機構と、送達機構に収容された組成物の少なくとも1つの投薬量とを備える治療送達器具であって、組成物が、治療上有効量の請求項1から29に記載の化合物もしくは化合物の組合せ、もしくはその薬学的に許容される塩、N−オキシド、水和物、溶媒和物、互変異性体もしくは光学異性体、又は請求項30に記載の医薬組成物である治療送達器具。
- 送達器具が、送達システムに収容された組成物の制御放出を可能にする、請求項36及び37の治療送達システム。
- 送達器具が、送達システムに収容された組成物の遅延放出を可能にする、請求項36及び37の治療送達システム。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862730046P | 2018-09-12 | 2018-09-12 | |
US62/730,046 | 2018-09-12 | ||
PCT/IB2019/057711 WO2020053812A1 (en) | 2018-09-12 | 2019-09-12 | Alkynyl nicotinamide compounds as kinase inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2022500390A true JP2022500390A (ja) | 2022-01-04 |
JPWO2020053812A5 JPWO2020053812A5 (ja) | 2022-09-22 |
JP7474752B2 JP7474752B2 (ja) | 2024-04-25 |
Family
ID=69776729
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021513385A Active JP7474752B2 (ja) | 2018-09-12 | 2019-09-12 | キナーゼ阻害剤としてのアルキニルニコチンアミド化合物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220089599A1 (ja) |
EP (1) | EP3849985A4 (ja) |
JP (1) | JP7474752B2 (ja) |
CN (1) | CN113227094A (ja) |
CA (1) | CA3112305A1 (ja) |
WO (1) | WO2020053812A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4175957A1 (en) * | 2020-06-24 | 2023-05-10 | Purdue Research Foundation | 2,3-disubstituted pyrido[3,4-b]pyrazine-containing compounds as kinase inhibitors |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2008008152A (es) * | 2005-12-23 | 2008-09-12 | Ariad Pharma Inc | Compuestos heterociclicos biciclicos. |
EP2841062A4 (en) * | 2012-04-25 | 2015-11-25 | Ariad Pharma Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES MEDIATED BY RAF KINASE |
WO2013170774A1 (zh) | 2012-05-16 | 2013-11-21 | 上海医药集团股份有限公司 | 具有抗肿瘤活性的乙炔衍生物 |
US20150291594A1 (en) | 2012-08-14 | 2015-10-15 | Concert Pharmaceuticals, Inc. | Deuterated Ponatinib |
CN104211639A (zh) | 2013-06-05 | 2014-12-17 | 中国科学院上海药物研究所 | 一类炔基杂环类化合物及其应用 |
CN104341425B (zh) * | 2013-08-08 | 2018-11-02 | 上海医药集团股份有限公司 | 氘代乙炔衍生物、其药物组合物及应用 |
EP3496717A4 (en) * | 2016-08-15 | 2020-01-15 | Purdue Research Foundation | AMINOISOQUINOLEIN DERIVATIVES SUBSTITUTED IN POSITION 4 |
-
2019
- 2019-09-12 CN CN201980067899.XA patent/CN113227094A/zh active Pending
- 2019-09-12 EP EP19860615.4A patent/EP3849985A4/en active Pending
- 2019-09-12 WO PCT/IB2019/057711 patent/WO2020053812A1/en unknown
- 2019-09-12 JP JP2021513385A patent/JP7474752B2/ja active Active
- 2019-09-12 CA CA3112305A patent/CA3112305A1/en active Pending
- 2019-09-12 US US17/274,950 patent/US20220089599A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN113227094A (zh) | 2021-08-06 |
JP7474752B2 (ja) | 2024-04-25 |
EP3849985A1 (en) | 2021-07-21 |
EP3849985A4 (en) | 2022-05-18 |
CA3112305A1 (en) | 2020-03-19 |
WO2020053812A4 (en) | 2020-05-07 |
WO2020053812A1 (en) | 2020-03-19 |
US20220089599A1 (en) | 2022-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102625807B (zh) | 4-取代的吡啶-3-基-甲酰胺化合物和使用方法 | |
CN102036990B (zh) | 新型酪氨酸激酶抑制剂 | |
KR101315610B1 (ko) | 브루톤 티로신 키나제 억제제 | |
US9532987B2 (en) | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases | |
CN107108671A (zh) | 作为raf激酶抑制剂的化合物和组合物 | |
TW201533028A (zh) | 用於激酶調節之化合物及其適應症 | |
JP2013500257A (ja) | Pi3kインヒビターでの肝障害の処置 | |
TW200902531A (en) | Imidazolopyrimidine analogs and their use as PI3 kinase and mTOR inhibitors | |
CN104974162B (zh) | 双环吡唑酮化合物及其使用方法和用途 | |
Baladi et al. | State-of-the-art of small molecule inhibitors of the TAM family: The point of view of the chemist | |
CN111053768A (zh) | 用于治疗黑素瘤的药物组合 | |
CN108779073A (zh) | 用于治疗癌症的组合物和方法 | |
CN109563088B (zh) | MEK/PI3K和mTOR/MEK/PI3K的多功能抑制剂和治疗用途 | |
JP2015007143A (ja) | 医薬組み合わせ | |
EP3227296B1 (en) | A deuterated triazolopyridazine as a kinase modulator | |
WO2014169710A1 (zh) | 激酶抑制剂及治疗相关疾病的方法 | |
Listro et al. | Urea-based anticancer agents. Exploring 100-years of research with an eye to the future | |
EP3466952A1 (en) | Novel inhibitor for flt3 kinase and uses thereof | |
CN102083829A (zh) | 改良的Raf抑制剂 | |
JP7474752B2 (ja) | キナーゼ阻害剤としてのアルキニルニコチンアミド化合物 | |
TW202021591A (zh) | B細胞惡性腫瘤之治療 | |
TW201609106A (zh) | 用於治療cns惡性病之btk抑制劑 | |
CN117529321A (zh) | Erk抑制剂和kras抑制剂的组合及其用途 | |
RU2780168C1 (ru) | Новое производное пиридо [3,4-d] пиримидин-8-она, обладающее ингибирующей протеинкиназы активностью, и фармацевтическая композиция для предупреждения, облегчения или лечения рака, содержащее указанное выше | |
US20180057479A1 (en) | Inhibitors of BCR-ABL Mutants and Use Thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A525 Effective date: 20210507 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220830 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220912 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220913 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230810 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230825 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231127 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240118 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240321 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240415 |